Stephen Hicks, Chairman and CEO of Southridge, LLC ("Southridge"), today announced that Southridge Partners II, an institutional investor, has entered into a $10 million equity purchase agreement with TechniScan, Inc. (OTC BB: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system.
We are excited to be TechniScan’s equity investor in this major phase of developing better breast cancer diagnostics,” said Mr. Hicks. "Southridge is committed to working with TechniScan in the vital research of this emerging technology."
We are excited to be TechniScan’s equity investor in this major phase of developing better breast cancer diagnostics,” said Mr. Hicks. "Southridge is committed to working with TechniScan in the vital research of this emerging technology."
Pursuant to a purchase agreement, TechniScan has the right, at its discretion, to sell to Southridge up to $10 million of its common stock over a 24-month period. The Company will have the right, but is not obligated, to sell stock to Southridge depending on certain conditions as set forth in the purchase agreement.
